Pfiz­er vs J&J: Re­searchers are duk­ing it out for the cham­pi­onship ti­tle in non­metasta­t­ic prostate can­cer

Pfiz­er $PFE and J&J $JNJ have come down to the wire with piv­otal da­ta on non­metasta­t­ic prostate can­cer. And there are bil­lions of dol­lars in rev­enue on the line here.

Both com­pa­nies post­ed their ab­stracts be­ing re­viewed at AS­CO’s Gen­i­touri­nary Can­cers Sym­po­sium Mon­day evening. And while sci­en­tists frown on com­par­ing da­ta from two dif­fer­ent stud­ies, you can bet that an­a­lysts will be lin­ing up the re­sults side-by-side to see who will come out ahead.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.